Notch is out — your watchlist beside the MacBook notch, synced with this account.
Learn more ↗We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Adaptive Biotechnologies Corporation은 상업화 단계의 기업으로, 다양한 질병의 진단 및 치료를 위한 면역 의학 플랫폼을 개발합니다. 동사는 독자적인 화학 기술, 계산 생물학, 머신러닝 기술을 통합하여 임상 면역체학 데이터를 생성하고 적응 면역 체계를 해독하는 면역 시퀀싱 플랫폼을 제공합니다. clonoSEQ 진단 검사를 통해 치료 중 및 치료 후 환자의 체내에 남아있는 암세포의 수, 즉 미세 잔존 질환(MRD)을 감지하고 모니터링합니다. 동사는 생명 과학 연구, 임상 진단 및 신약 개발 분야를 위한 제품과 서비스를 제공합니다. 동사는 이전에 Adaptive TCR Corporation으로 알려졌으며, 2011년 12월 Adaptive Biotechnologies Corporation으로 사명을 변경했습니다. Adaptive Biotechnologies Corporation은 2009년에 설립되었으며, 워싱턴주 시애틀에 본사를 두고 있습니다.
